Cantor Fitzgerald Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target boosted by investment analysts at Cantor Fitzgerald from $1,440.00 to $1,600.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective suggests a potential upside of 13.02% from the company’s current price.

LLY has been the subject of a number of other research reports. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 26th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Argus raised their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Truist Financial reissued a “buy” rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,404.14.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,415.64 on Monday. The company has a market cap of $1.33 trillion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock’s fifty day moving average price is $1,197.72 and its 200-day moving average price is $1,092.57. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period in the previous year, the company posted $7.02 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Bank of America Corp DE purchased a new position in Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $4,667,180,000. Fifth Third Bancorp raised its holdings in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $764,116,000. Finally, BlackRock Inc. lifted its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and guidance underpin the rally. Eli Lilly reported third-quarter revenue growth of approximately 39%, led by Mounjaro and Zepbound, and raised its full-year outlook. The company reportedly delivered earnings and revenue above analyst expectations, helping drive the shares to record levels. Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
• Positive Sentiment: Volume growth is offsetting lower prices. Coverage highlights that Eli Lilly grew revenue even after reducing GLP-1 prices by about 15%, suggesting demand remains strong and that lower prices could expand access to a larger patient market. Eli Lilly stock surges as cheaper drugs unlock a bigger market
• Positive Sentiment: Analyst confidence remains high. Several reports describe higher price targets, including targets near $1,600, while Keith McCullough reiterated his bullish LLY recommendation. Eli Lilly and Company Price Target Raised to $1,596.00
• Neutral Sentiment: Manufacturing expansion could support long-term growth. Goochland officials are considering a workforce-development pipeline linked to Eli Lilly’s planned $5 billion plant, which could help address future staffing needs. Goochland Weighs Direct Pipeline From High School Halls to Eli Lilly’s $5B Plant
• Negative Sentiment: Pricing and valuation are key risks. Medicare’s GLP-1 Bridge program and additional price cuts may pressure margins, while the stock’s sharp advance and premium valuation leave less room for execution disappointments. Optimistic long-term projections also acknowledge that future returns may be slower than the recent gains.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.